Compare NXP & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXP | GERN |
|---|---|---|
| Founded | N/A | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.2M | 808.3M |
| IPO Year | 1995 | N/A |
| Metric | NXP | GERN |
|---|---|---|
| Price | $14.15 | $1.19 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.17 |
| AVG Volume (30 Days) | 109.8K | ★ 13.1M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.73 | $1.04 |
| 52 Week High | $14.65 | $2.01 |
| Indicator | NXP | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 32.24 |
| Support Level | $13.94 | $1.05 |
| Resistance Level | $14.51 | $1.30 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 42.19 | 25.00 |
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.